Pancreas Cancer News and Archives
	Aphton Presented Phase III Data for Monotherapy with G17DT for Advanced Pancreatic Cancer Patients to Overseas Regulatory Agency Prepares for Filing for Approval to Market in the EU, Canada And Australia Miami, Florida March 4, 2003 Aphton Corporation announced today that the company has met with and presented results of its randomized, double blind, controlled, monotherapy, Phase III clinical trial conducted in Europe with G17DT for patients with advanced pancreatic cancer to an appropriate foreign regulatory authority. The presentation of the most recently completed analysis of the data demonstrated an overall median survival benefit of 83%, with a statistically significant value of p. The corresponding hazard ratio (HR) was 0.65, which also had a statistically significant value of p. (HR of 0.65 means that at any point in time, patients on G17DT had a 154% higher likelihood of surviving longer than patients on the control.) There are still surviving, treated patients in the trial. Their standard of care could be influenced, thereby jeopardizing both their inclusion in the final statistical analysis and the ultimate breadth of the indication allowed in each jurisdiction, if additional specifics on the trial were provided at this time. ...full article
	For educational purposes only; not to be relied upon Please read Pancreatica Disclaimer
	Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us
	webmaster
	©2000-2008 Pancreatica.org - All Rights Reserved www.pancreatica.org